CAR-T Therapies
CAR-T therapies engineer a patient’s T-cells with synthetic receptors to hunt cancer antigens precisely. Since 2017, they treat blood cancers and offer hope for incurable forms like multiple myeloma.
CAR-T therapies (Chimeric Antigen Receptor T-cell therapies) are a form of next-generation cell treatment where a patient’s own T-cells are genetically engineered to express a synthetic receptor that binds to specific antigens on cancer cells. First introduced in 2017, they are now approved for various blood cancers like multiple myeloma and are being explored for childhood brain cancers, offering hope for otherwise incurable conditions by enabling the immune system to precisely target and destroy tumors.
What this means in real life
A child with acute lymphoblastic leukemia receives CAR-T therapy: doctors remove some of their T cells, reprogram them to hunt leukemia cells, grow millions of copies in the lab, and infuse them back. The engineered cells multiply and eliminate the cancer.
What it isn’t
It is not a standard chemotherapy drug or a vaccine. CAR-T is a living cellular therapy—the patient's own modified cells do the work, not a chemical compound administered directly.
Commonly misused online
Social media often presents CAR-T as a universal cancer cure, when in reality it is approved only for specific blood cancers and solid tumors, and not all patients respond or tolerate it equally.
Based on 2 reference sources, including reference sources. Last verified July 12, 2026.